EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026

2017-06-12
Price :
Published : Jun-2017
No. of Pages : 56

EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026

Summary

Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body (AHA, 2015a). HF commonly occurs in people older than 50 years of age, and severity increases progressively with age (Mosterd and Hoes, 2007). The symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF (CHF), the symptoms develop gradually (NHS, 2014).

Eventually, without the heart’s pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing stairs, or carrying weight can become tedious.

In the 7MM, it is forecast that the diagnosed incident cases of HF will increase from 1,990,569 cases in 2016 to 2,468,827 cases in 2026 at an annual growth rate (AGR) of 2.40%. The US had the highest number of diagnosed incident cases of HF in the 7MM in both 2016 and 2026, at 827,525 cases in 2016, and 1,081,878 cases in 2026.

In the 7MM, epidemiologists forecast that the diagnosed prevalent cases of CHF will increase from 14,403,423 cases in 2016 to 17,127,297 cases in 2026 at an AGR of 1.89%. The US had the highest number of diagnosed prevalent cases of CHF in the 7MM in both 2016 and 2026, at 5,816,242 cases in 2016, and 7,115,415 cases in 2026.

The report “EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026” provides an overview of the risk factors, comorbidities, and the global trends for HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction.

Scope

– The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction. The diagnosed prevalent cases of CHF, CHF with REF, and CHF with PEF are further classified according to the New York Heart Association (NYHA) functional classes I-IV. The diagnosed incident cases of HF and diagnosed prevalent cases of CHF are segmented by age (at 10-year intervals, for ages 45 years and older) and sex.
– The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Heart Failure EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global HF market.
– Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
– Understand HF cases patient distribution by ejection fraction and NYHA functional classes.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Pathology Market by Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), End-User (Pharmaceutical Companies, Hospitals) – Global Forecast to 2025

“The digital pathology market is projected to grow at a CAGR of 13.8% during the forecast period (2020–2025).” The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8% during the forecast period. The key factors driving the growth of this market include the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, growing application of digital pathology in drug development & companion diagnostics, and increasing initiatives by industry players. However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent. “Adoption of artificial intelligence is expected to increase during the forecast period.” The adop......
$4950

Netherlands Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Netherlands Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "Netherlands Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in the Netherlands. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-hous......
$1995

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol), Region – Global Forecast to 2025

The pharmaceutical packaging equipment market is expected to grow at a CAGR of 7.4% in the forecast period. The global pharmaceutical packaging equipment market size is projected to reach USD 10.4 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 7.4% from 2020 to 2025. The growth of the market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible & integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, and the introduction of regulatory standards on packaging & stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are expected to restrain market growth to a cer......
$4950

Measles Disease – Global Clinical Trials Review, H2, 2020

Measles Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Measles Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Measles Clinical trials scenario. This report provides top line data relating to the clinical trials on Measles. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials a......
$2500

Menorrhagia Disease – Global Clinical Trials Review, H2, 2020

Menorrhagia Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Menorrhagia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Menorrhagia Clinical trials scenario. This report provides top line data relating to the clinical trials on Menorrhagia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. C......
$2500

Microalbuminuria Disease – Global Clinical Trials Review, H2, 2020

Microalbuminuria Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Microalbuminuria Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Microalbuminuria Clinical trials scenario. This report provides top line data relating to the clinical trials on Microalbuminuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Sciatica (Sciatic Pain) Disease – Global Clinical Trials Review, H2, 2020

Sciatica (Sciatic Pain) Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Sciatica (Sciatic Pain) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Sciatica (Sciatic Pain) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sciatica (Sciatic Pain). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Central Retinal Vein Occlusion Disease – Global Clinical Trials Review, H2, 2020

Central Retinal Vein Occlusion Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Central Retinal Vein Occlusion Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Central Retinal Vein Occlusion Clinical trials scenario. This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Malignant Pleural Effusion Disease – Global Clinical Trials Review, H2, 2020

Malignant Pleural Effusion Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Malignant Pleural Effusion Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Malignant Pleural Effusion Clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Pleural Effusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Primary Immune Deficiency (PID) Disease – Global Clinical Trials Review, H2, 2020

Primary Immune Deficiency (PID) Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Primary Immune Deficiency (PID) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Primary Immune Deficiency (PID) Clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Immune Deficiency (PID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy